MARAVAI LIFESCIENCES HOLDINGS, INC.

Annual Trend FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Depreciation $3.8m $5.5m $6.4m $7.6m $12.9m $20.9m $23.6m
Amortization of intangible assets $20.3m $20.3m $18.3m $24.3m $27.4m $27.5m $28.0m
Amortization of operating lease right-of-use assets $0 $0 $8.8m $6.3m $8.5m $8.5m $9.0m
Amortization of deferred financing costs $1.7m $1.8m $2.7m $2.8m $2.9m $2.9m $1.7m
Deferred income taxes ($1.2m) ($5.5m) $46.9m $42.3m $754.9m $11k ($20k)
Impairment $0 $166.2m $84.6m
Loss on extinguishment of debt $0 $7.6m $0 $208k $0 $3.2m $0
Right-of-use assets obtained in exchange for operating lease liabilities $0 $0 $17.5m $3.9m $1.3m $463k
Net loss ($5.2m) $78.8m $469.2m $490.7m ($138.4m) ($259.6m) ($230.8m)
Stock-based compensation expense $1.7m $24.6m $10.5m $18.7m $34.6m $49.4m $30.2m
Change in estimated fair value of contingent consideration $0 $0 ($7.8m) ($3.3m) ($2.0m) $0
Revaluation of liabilities under the Tax Receivable Agreement $0 $0 ($6.1m) $4.1m ($668.9m) $40k $0
Acquisition related tax adjustment $349k $1.3m $2.3m $4.1m
Other $688k $2.4m ($281k) ($8.0m) ($2.3m) $833k $212k
Accounts receivable ($1.9m) ($33.1m) ($70.4m) ($22.3m) $84.4m $14.4m $12.8m
Inventory $106k ($19.1m) ($21.6m) $9.5m $649k $377k $8.0m
Prepaid expenses and other current assets ($2.0m) ($5.5m) ($9.5m) ($52.9m) $8.1m $2.0m $1.6m
Other assets $861k $153k $181k
Accounts payable $2.5m $1.2m $676k ($1.6m) $5.3m $723k ($7.3m)
Accrued expenses and other current liabilities $3.5m $17.8m ($3.5m) $8.5m $15.1m ($22.8m) ($4.6m)
Other long-term liabilities $0 ($2.5m) ($4.5m) $3.8m ($16.0m) ($6.3m) ($18.6m)
Purchases of property and equipment ($17.1m) ($25.4m) ($14.8m) ($17.1m) ($65.6m) ($29.7m) ($13.1m)
Proceeds from government assistance allocated to property and equipment $15k $0 $0 $1.1m $12.9m $7.1m $734k
Refunds (distributions) for tax liabilities to non-controlling interests holder ($9.6m) ($494k) $10k
Financing costs paid to acquire long-term debt $0 ($9.3m) $0 $0 $0 ($1.2m) $0
Proceeds from interest rate cap agreement $0 $0 $6.2m $9.3m $1.4m
Payments of acquisition related contingent consideration and consideration holdback ($1.3m) ($1.4m) $0 $0 ($9.7m) $0 ($6.8m)
Payments pursuant to the Tax Receivable Agreement $0 $0 ($1.3m) ($34.2m) ($42.2m) ($7.1m) $0
Property and equipment included in accounts payable and accrued expenses $2.8m $2.0m $2.1m $1.7m $2.0m $2.6m $3.7m
Accrued receivable for capital expenditures to be reimbursed under a government contract $0 $0 $1.1m $734k $0
Right-of-use assets obtained in exchange for finance lease liabilities $0 $0 $32.9m $0 $0
Fair value of contingent consideration liability recorded in connection with acquisition of a business $0 $0 ($7.8m) $5.3m $0 $0
Net cash (used in) provided by operating activities $24.1m $152.2m $368.6m $536.0m $126.2m $7.5m ($57.6m)
Cash paid for acquisitions of a business, net of cash acquired $0 ($239.0m) ($69.6m) $0 ($19.0m)
Other investing activities, net $0 ($1.8m) $0
Net cash used in investing activities ($17.1m) $6.1m $105.7m ($267.6m) ($122.3m) ($24.3m) ($31.4m)
Principal repayments of long-term debt ($2.5m) ($411.9m) ($6.0m) ($13.9m) ($5.4m) ($234.4m) ($5.4m)
Other financing activities, net ($352k) ($1.8m) ($5.6m)
Net cash used in financing activities ($4.2m) $53.2m ($159.0m) ($187.5m) ($61.1m) ($235.7m) ($16.5m)
Effects of exchange rate changes on cash $34k $17k ($88k) $0 $0 $0 ($32k)
Net decrease in cash and cash equivalents $2.8m $211.5m $315.1m $80.9m ($57.2m) ($252.6m) ($105.5m)
Cash and cash equivalents, beginning of period $24.7m $236.2m $551.3m $632.1m $575.0m $322.4m $216.9m
Cash paid for interest $28.7m $28.9m $27.2m $20.2m $44.3m $51.0m $25.0m
Cash (refunded) paid for income taxes, net $802k $5.0m $22.5m $23.0m ($3.0m) $670k ($555k)